Characteristics of patients with epithelioid hemangioendothelioma (EHE): a retrospective analysis of the Charité-Universitätsmedizin Berlin.
Molecular profiling clarifies this rare blood vessel cancer's genetics, guiding future trial design and prognosis assessment.
This single-center retrospective of 41 EHE patients at Charité Berlin confirms the clinical heterogeneity of this ultra-rare vascular sarcoma, with most patients showing indolent disease and a subset requiring aggressive intervention. The molecular profiling data (WWTR1-CAMTA1 fusion prevalence, TFE3 expression) adds to a small but growing evidence base for EHE molecular classification to guide clinical trial eligibility.
What the study was
- Study design
- retrospective_single_center
- Population
- Epithelioid hemangioendothelioma patients
- Sample size
- 41
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Journal of Cancer Research and Clinical Oncology
Why it surfaced
EHE is an ultra-rare vascular sarcoma with no established systemic therapy; molecular characterization data from a European cancer center contributes to the limited evidence base; trial design for rare vascular tumors requires this type of natural history data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.